Sulindac-d3 (Synonyms: MK-231-d3) |
| Catalog No.GC48677 |
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Sulindac-d3 is intended for use as an internal standard for the quantification of sulindac by GC- or LC-MS. Sulindac is a non-steroidal anti-inflammatory drug (NSAID), selective COX-2 inhibitor (IC50s = 0.79 and >1,000 µM for COX-2 and COX-1, respectively), and prodrug form of sulindac sulfide .1,2,3,4 Sulindac is reduced by intestinal bacteria to form sulindac sulfide.1 It inhibits acetic acid-induced writhing in mice and reduces paw edema induced by carrageenan in rats when administered at a dose of 100 mg/kg.3 Sulindac (60 mg/kg) reduces tumor growth in MiaPaCa-2 and BxPC-3 mouse xenograft models.4 Formulations containing sulindac have been used in the treatment of pain associated with arthritis, ankylosing spondylitis, and gout.
1.Maseda, D., and Ricciotti, E.NSAID-gut microbiota interactionsFront. Pharmacol.111153(2020) 2.Grossman, C.J., Wiseman, J., Lucas, F.S., et al.Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDs and Cox 2 inhibitorsInflamm. Res.44(6)253-257(1995) 3.Bhat, M.A., Al-Omar, M.A., Alsaif, N.A., et al.Novel sulindac derivatives: Synthesis, characterisation, evaluation of antioxidant, analgesic, anti-inflammatory, ulcerogenic and COX-2 inhibition activityJ. Enzyme Inhib. Med. Chem.35(1)921-934(2020) 4.Yip-Schneider, M.T., Wu, H., Ralstin, M., et al.Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivoMol. Cancer Ther.6(6)1736-1744(2007)
| Cas No. | SDF | ||
| Sinónimos | MK-231-d3 | ||
| Canonical SMILES | OC(CC1=C(C)/C(C2=CC=C(F)C=C21)=C/C3=CC=C(C=C3)S(C([2H])([2H])[2H])=O)=O | ||
| Formula | C20H14D3FO3S | M.Wt | 359.4 |
| Solubility | DMSO : 50 mg/mL (140.29 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble) | Storage | -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7824 mL | 13.9121 mL | 27.8242 mL |
| 5 mM | 556.5 μL | 2.7824 mL | 5.5648 mL |
| 10 mM | 278.2 μL | 1.3912 mL | 2.7824 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *